About Vactech

"We develop and license vaccines and novel technologies for vaccines and diagnostics."

Vactech is a company with a pipeline of early stage product candidates focused on Type 1 Diabetes, Celiac Disease, Asthma & Allergy and diagnostics. The primary focus of our research and product development is to unravel and treat the complexities of immune-mediated diseases and enteroviruses.

Starting in 2001, our company was founded on the principle of only selecting and pursing research that could lead to the greatest academic and commercial success. Today our founders continue this mission of only pursuing research that produces results with high commercial impact. The research that is chosen does not only show great academic promise, but also the ability to yield relevant IRP, product development and commercialization.

Our founders are world renowned and clinical leaders in the fields of Type 1 Diabetes, enteroviruses vaccines, antiviral treatments, immunomodulatory stimulation and diagnostic applications. As such, they have been recognized by several international research grants and awards and been acknowledged as invited speakers in many international congresses.

Vactech’s flagship project is a patented enterovirus based preventive Type 1 Diabetes (T1D) vaccine, similar to the widely used enterovirus vaccine against polio. Currently around 15 million people worldwide are affected by T1D, and its prevalence is rapidly increasing. With modest target and penetration parameters the revenue of the vaccine is expected to be more than 5 billion dollars only in US and EU during the first 10 years following the market introduction.

Vactech’s vaccine is not only targeting this increasing health problem but will additionally prevent other diseases caused by enteroviruses. Such diseases cause a huge burden to the society and include common cold, otitis media, hand, foot and mouth disease, central nervous system infections and heart infections.

The suggested vaccine recipe is based on a huge biobank with more than 200,000 children screened for genetic predisposition to T1D. The vaccine is a traditional inactivated vaccine and it has been proved to be safe and effective in mice. In addition, Vactech’s IMAVAC™ product line uses Virus Like Particle (VLP) technology which is essential for other vaccines, immunomodulators and diagnostic applications.

Vactech is a privately owned company, which allows for quick and flexible decision making. We have used this advantage to operate with a light kernel organization on a project basis, outsource work when appropriate and necessary, and create strategic collaborations. We have a track record of collaboration with big pharma on the level of Good Laboratory Practice (GLP). We consider ourselves as an attractive investment target for those that believe in and want to grow with our mission.